SCHEMBL19686887

SCHEMBL19686887

Cc1cc(C)n(-c2cc(O)cc(NC3CCC(F)(F)CC3)n2)n1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNN2 Q9H2S1 1/20 0.48
KCNN3 Q9UGI6 1/20 0.48
IDH1 O75874 5/20 0.38
SMN1; SMN2 Q16637 2/20 0.37
TSHR P16473 1/20 0.37
MAPT P10636 2/20 0.36
ADORA2A P29274 3/20 0.35
KDM4E B2RXH2 2/20 0.35
NR2F2 P24468 2/20 0.35
NPSR1 Q6W5P4 2/20 0.35
MAPK1 P28482 1/20 0.35
GAA P10253 2/20 0.35
ADORA1 P30542 2/20 0.34
LMNA P02545 2/20 0.34
MEN1 O00255 1/20 0.34
NPC1 O15118 1/20 0.34
S1PR2 O95136 1/20 0.34
ALDH1A1 P00352 1/20 0.34
XBP1 P17861 1/20 0.34
RAB9A P51151 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19686284 0.89 KCNN2 (0.49) KCNN2KCNN3IDH1SMN1; SMN2TSHR
SCHEMBL19686732 0.87 KCNN3 (0.47) KCNN2KCNN3IDH1SMN1; SMN2TSHR
SCHEMBL21144126 0.87 KCNN2 (0.45) KCNN2KCNN3IDH1SMN1; SMN2TSHR
SCHEMBL19686944 0.87 KCNN2 (0.45) KCNN2KCNN3IDH1SMN1; SMN2TSHR
SCHEMBL19687522 0.86 KCNN2 (0.44) KCNN2KCNN3IDH1SMN1; SMN2TSHR
SCHEMBL19687525 0.86 KCNN2 (0.44) KCNN2KCNN3IDH1MAPTADORA2A
SCHEMBL31127116 0.86 KCNN2 (0.44) KCNN2KCNN3IDH1MAPTADORA2A
SCHEMBL19686941 0.85 KCNN2 (0.46) KCNN2KCNN3IDH1SMN1; SMN2TSHR
SCHEMBL19686935 0.85 KCNN2 (0.46) KCNN2KCNN3IDH1SMN1; SMN2TSHR
SCHEMBL31127312 0.85 KCNN2 (0.46) KCNN2KCNN3IDH1SMN1; SMN2TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240317705-A1 POTASSIUM CHANNEL MODULATORS NOVARTIS AG (CH) 2024-09-26 US disclosed
US-10774064-B2 Potassium channel modulators CADENT THERAPEUTICS, INC. (US) 2020-09-15 US disclosed
US-10774064-B2 Potassium channel modulators CADENT THERAPEUTICS, INC. (US) 2020-09-15 US disclosed
US-20190218200-A1 POTASSIUM CHANNEL MODULATORS NOVARTIS AG (CH) 2019-07-18 US disclosed
US-20190218200-A1 POTASSIUM CHANNEL MODULATORS NOVARTIS AG (CH) 2019-07-18 US disclosed
WO-2017139697-A9 BACTERIA ENGINEERED TO TREAT DISEASES ASSOCIATED WITH HYPERAMMONEMIA SYNLOGIC, INC. (US) 2017-12-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240317705-A1 POTASSIUM CHANNEL MODULATORS KCNJ11, KCNJ2, KCNJ1 KCNN2 5/4885KCNN3 11/4885IDH1 3017/4885
US-10774064-B2 Potassium channel modulators KCNJ11, KCNJ2, KCNJ1 KCNN2 5/4885KCNN3 11/4885IDH1 3017/4885
US-20190218200-A1 POTASSIUM CHANNEL MODULATORS KCNJ11, KCNJ2, KCNJ1 KCNN2 5/4885KCNN3 11/4885IDH1 3017/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.